Cardiac Resynchronization Therapy Market: Market Size & Forecast 2026

Cardiac Resynchronization Therapy is a clinically established treatment for patients with heart failure and ventricular dyssynchrony, involving the implantation of a pulse generator that resynchronizes heart chamber contractions. The global market is segmented by product type into CRT-Defibrillators (CRT-D), which combine resynchronization with defibrillation capability, and CRT-Pacemakers (CRT-P), which provide pacing without defibrillation. These devices are delivered through hospitals, specialized cardiac centers, and ambulatory surgical facilities.

• •Market valued at $6.72 billion in 2025 with a projected CAGR of 5.7% through the early 2030s
• •Two primary product segments: CRT-Defibrillators (the larger segment) and CRT-Pacemakers
• •Key end-use channels include hospitals, cardiac centers, and other healthcare facilities

The growing global burden of heart failure, exacerbated by rising rates of hypertension, diabetes, and coronary artery disease, is a primary driver of CRT device demand. An aging worldwide population, particularly in developed economies, contributes to higher prevalence of cardiac conduction disorders suitable for CRT treatment. Ongoing device miniaturization, extended battery longevity, MRI-conditional designs, and remote monitoring capabilities are expanding the eligible patient population and encouraging physician adoption.

• •Increasing prevalence of heart failure globally, linked to aging demographics and lifestyle-related comorbidities
• •Technological advancements including leadless designs, MRI-conditional devices, and remote monitoring features
• •Expanding clinical indications for CRT and improving patient awareness of treatment options

The market is bifurcated between CRT-Defibrillators, which dominate due to their dual therapeutic and protective functions, and CRT-Pacemakers, which serve patients with specific pacing needs. By end-use, hospitals account for the largest share, while cardiac centers and electrophysiology labs represent a growing distribution channel. Geographically, North America leads the market with high device penetration and favorable reimbursement, while Europe holds a substantial and stable share; Asia-Pacific is projected to grow at the fastest rate due to improving healthcare infrastructure and rising disease prevalence.

• •North America commands the largest regional share, supported by advanced healthcare infrastructure and reimbursement frameworks
• •Asia-Pacific is the fastest-growing region, driven by rising heart failure burden and expanding healthcare access
• •Europe represents a mature market with steady demand and ongoing device upgrades

What are the recent trends and outlook?

The market is poised for sustained growth through 2035, with the industry continuing to shift toward minimally invasive procedures and devices with enhanced connectivity for remote patient management. The development of leadless and subcutaneous CRT systems represents an emerging innovation frontier aimed at reducing procedure-related complications. Favorable regulatory approvals, broadening insurance coverage, and the global transition toward value-based care models are expected to support steady market expansion at approximately 5.7% annually over the forecast horizon.

• •Projected market expansion to approximately $7.18 billion in the near term and up to $18.33 billion by 2035 under broader market definitions
• •Emerging focus on leadless and subcutaneously implantable CRT systems to reduce lead-related complications
• •Growing adoption of remote monitoring and telehealth integration aligning with value-based care and chronic disease management